Dr. Reddy’s Laboratories Limited (NYSE:RDY) Shares Acquired by Lester Murray Antman dba SimplyRich

Lester Murray Antman dba SimplyRich increased its holdings in shares of Dr. Reddy’s Laboratories Limited (NYSE:RDY) by 465.6% in the fourth quarter, Holdings Channel reports. The firm owned 37,423 shares of the company’s stock after buying an additional 30,806 shares during the period. Lester Murray Antman dba SimplyRich’s holdings in Dr. Reddy’s Laboratories were worth $590,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Augustine Asset Management Inc. increased its holdings in Dr. Reddy’s Laboratories by 392.6% in the 4th quarter. Augustine Asset Management Inc. now owns 249,744 shares of the company’s stock valued at $3,943,000 after purchasing an additional 199,044 shares during the last quarter. POM Investment Strategies LLC boosted its position in shares of Dr. Reddy’s Laboratories by 400.0% during the fourth quarter. POM Investment Strategies LLC now owns 2,275 shares of the company’s stock worth $36,000 after buying an additional 1,820 shares during the period. XY Capital Ltd acquired a new stake in shares of Dr. Reddy’s Laboratories in the fourth quarter valued at $1,061,000. Savant Capital LLC purchased a new stake in shares of Dr. Reddy’s Laboratories in the 4th quarter valued at $220,000. Finally, Migdal Insurance & Financial Holdings Ltd. lifted its stake in Dr. Reddy’s Laboratories by 217.5% during the 4th quarter. Migdal Insurance & Financial Holdings Ltd. now owns 100,000 shares of the company’s stock worth $1,571,000 after acquiring an additional 68,500 shares in the last quarter. 3.85% of the stock is currently owned by hedge funds and other institutional investors.

Dr. Reddy’s Laboratories Trading Up 0.0 %

NYSE:RDY opened at $13.82 on Wednesday. The stock has a fifty day moving average price of $14.76 and a 200 day moving average price of $15.34. The company has a current ratio of 1.92, a quick ratio of 1.38 and a debt-to-equity ratio of 0.02. Dr. Reddy’s Laboratories Limited has a 12-month low of $13.36 and a 12-month high of $16.89. The firm has a market cap of $11.53 billion, a PE ratio of 22.00 and a beta of 0.50.

Dr. Reddy’s Laboratories (NYSE:RDY) last announced its quarterly earnings data on Thursday, January 23rd. The company reported $0.20 EPS for the quarter, topping analysts’ consensus estimates of $0.19 by $0.01. Dr. Reddy’s Laboratories had a return on equity of 17.87% and a net margin of 17.25%. Sell-side analysts anticipate that Dr. Reddy’s Laboratories Limited will post 0.8 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have weighed in on RDY shares. StockNews.com downgraded Dr. Reddy’s Laboratories from a “buy” rating to a “hold” rating in a research report on Friday, December 6th. Nomura cut shares of Dr. Reddy’s Laboratories from a “buy” rating to a “neutral” rating in a report on Thursday, December 19th. Finally, Barclays reduced their target price on shares of Dr. Reddy’s Laboratories from $17.40 to $17.00 and set an “overweight” rating on the stock in a report on Wednesday, November 6th.

Dr. Reddy’s Laboratories Profile

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.